 Generation Bio Co. GBIO, an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its initial public offering of 12,105,263 shares of its common stock at an initial public offering price of 19.00 per share, including 1,578,947 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Generation Bio. The shares began trading on the Nasdaq Global Select Market on Friday, June 12, 2020 under the ticker symbol GBIO. 